Gastroenterology
Survivin halts gastric cancer tumorigenicity and angiogenesis
Published in Gene Therapy Weekly, January 15th, 2004
"Survivin plays an important role in cancer development. We aim to show here that suppression of survivin expression or function by antisense and dominant-negative (DN) mutant can inhibit gastric cancer carcinogenesis and angiogenesis in vivo. Plasmid constructs expressing survivin antisense and DN mutant replacing the cysteine residue at amino acid 84 with alanine (Cys84Ala) were prepared and introduced into BCG-823 and MKN-45 gastric cancer cells to establish stable transfectants," scientists in the Peoples Republic of China report.
"We showed that both antisense and DN mutant stable...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-01-15)
More Articles from Gene Therapy Weekly
- Cancer Therapy
Interleukin-24 gene therapy shows promise in the fight against prostate cancer - Brain Cancer
Liposomal delivery offers clinical gene therapy for brain tumors - Brain Cancer
New MRI contrasts discern response to gene therapy in rodent glioma models - Breast Cancer
Unusual interleukin-8 gene methylation correlates with breast cancer metastasis - Chagas Disease
Free fatty acids induce cell differentiation in Trypanosoma cruzi - Diagnostics
Rapid identification method for E. coli O157:H7 using real-time PCR developed - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
